Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin’s lymphoma
David Frame(Rush University), Monalisa Ghosh(Michigan Medicine), Salena Kasha(University of Michigan), Attaphol Pawarode(University of Michigan), John Maciejewski(University of Michigan), Denise Markstrom(Michigan Medicine), Mary Riwes(University of Michigan), Andrew Hayduk(University of Michigan), Gianni B. Scappaticci(Michigan Medicine), Tate Feeney(Michigan Medicine), Sung Won Choi(University of Michigan), Sarah Anand(University of Michigan), Muneesh Tewari(University of Michigan), Avery Oberfeld(University of Michigan), Hannah D’Antonio(University of Michigan), Marcus Geer(University of Michigan), Hilary M. Mansoor(University of Michigan), John Magenau(University of Michigan)
Cited by 8
Related Papers
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells
|Cancer Research|2011|510
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
|Clinical Infectious Diseases|2020|501